<DOC>
	<DOC>NCT00755833</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control when using NovoMix® 50 up to 12 months after initiation subjects with type 2 diabetes currently on a therapy with human biphasic insulin. An additional objective is also to observe the different regimes of starting and maintaining the treatment with NovoMix® 50 during one year.</brief_summary>
	<brief_title>Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes treated with biphasic human insulin with or without metformin Inadequate glycaemic control or is experiencing hypoglycaemic events or would, in the physician's opinion, benefit from treatment with NovoMix® 50 Subjects with diagnosed type 1 diabetes mellitus Subjects treated with short acting or intermediate acting human insulin or any insulin analogue Subjects who are unlikely to comply with study description, e.g. uncooperative attitude, inability to come for regular visits Subjects with a hypersensitivity to biphasic insulin aspart 50 (NovoMix® 50 )or to any of the excipients Women of childbearing potential, who are pregnant, breastfeeding or intend to become pregnant within next 12 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>